• 1. Tricyclic xanthine derivatives containing a basic substituent: adenosine receptor affinity and drug-related properties
  Micha? Za?uski,Katarzyna Stanuch,Tadeusz Karcz,Sonja Hinz,Gniewomir Latacz,Ewa Szymańska,Jakub Schabikowski,Agata Doro?-P?onka,Jadwiga Handzlik,Anna Drabczyńska,Christa E. Müller,Katarzyna Kie?-Kononowicz Med. Chem. Commun. 2018 9 951
• 2. Studies on enantioselectivity of chiral 4-acetylamino-6-alkyloxy-2-alkylthiopyrimidines acting as antagonists of the human A3 adenosine receptor
  Barbara Cosimelli,Giovanni Greco,Sonia Laneri,Ettore Novellino,Antonia Sacchi,Simona Collina,Daniela Rossi,Sandro Cosconati,Elisabetta Barresi,Sabrina Taliani,Maria Letizia Trincavelli,Claudia Martini Med. Chem. Commun. 2018 9 81
• 3. Methoxy substituted 2-benzylidene-1-indanone derivatives as A1 and/or A2A AR antagonists for the potential treatment of neurological conditions
  Helena D. Janse van Rensburg,Lesetja J. Legoabe,Gisella Terre'Blanche,Mietha M. Van der Walt Med. Chem. Commun. 2019 10 300
• 4. Bitopic fluorescent antagonists of the A2A adenosine receptor based on pyrazolo[4,3-e][1,2,4]triazolo[1,5-c]pyrimidin-5-amine functionalized congeners
  Romain Duroux,Antonella Ciancetta,Philip Mannes,Jinha Yu,Shireesha Boyapati,Elizabeth Gizewski,Said Yous,Francisco Ciruela,John A. Auchampach,Zhan-Guo Gao,Kenneth A. Jacobson Med. Chem. Commun. 2017 8 1659
• 5. Bitopic fluorescent antagonists of the A2A adenosine receptor based on pyrazolo[4,3-e][1,2,4]triazolo[1,5-c]pyrimidin-5-amine functionalized congeners
  Romain Duroux,Antonella Ciancetta,Philip Mannes,Jinha Yu,Shireesha Boyapati,Elizabeth Gizewski,Said Yous,Francisco Ciruela,John A. Auchampach,Zhan-Guo Gao,Kenneth A. Jacobson Med. Chem. Commun. 2017 8 1659

1,3-Dipropylxanthine (CAS No. 31542-62-8): An Overview of Its Properties, Applications, and Recent Research

1,3-Dipropylxanthine (CAS No. 31542-62-8) is a synthetic xanthine derivative that has garnered significant attention in the fields of pharmacology and medicinal chemistry due to its unique properties and potential therapeutic applications. This compound is structurally similar to other xanthines such as caffeine and theophylline, but it exhibits distinct pharmacological effects that make it a valuable candidate for various research and clinical purposes.

The chemical structure of 1,3-Dipropylxanthine consists of a xanthine core with propyl groups attached to the 1 and 3 positions. This specific substitution pattern confers the compound with enhanced lipophilicity and altered binding affinities to adenosine receptors, which are key targets in the modulation of various physiological processes. The adenosine receptor family includes four subtypes (A₁, A_2A, A_2B, and A₃), each with distinct roles in the central nervous system (CNS) and peripheral tissues.

1,3-Dipropylxanthine has been extensively studied for its ability to act as a selective antagonist of adenosine A₁ receptors. This property makes it particularly useful in investigating the role of A₁ receptors in various neurological disorders, including Parkinson's disease, Alzheimer's disease, and epilepsy. Recent research has shown that 1,3-Dipropylxanthine can modulate neurotransmitter release and neuronal excitability, potentially offering neuroprotective benefits.

In addition to its neuroprotective effects, 1,3-Dipropylxanthine has been explored for its potential in treating respiratory conditions. Studies have demonstrated that this compound can improve bronchial smooth muscle relaxation and reduce airway inflammation, making it a promising candidate for the management of asthma and chronic obstructive pulmonary disease (COPD). The mechanism underlying these effects is thought to involve the inhibition of phosphodiesterase enzymes and the subsequent increase in cyclic adenosine monophosphate (cAMP) levels.

The pharmacokinetic properties of 1,3-Dipropylxanthine have also been well-characterized. It exhibits good oral bioavailability and a relatively long half-life, which are advantageous for sustained therapeutic effects. However, like other xanthines, it can interact with certain drugs and may require dose adjustments in patients with hepatic or renal impairment. Therefore, careful monitoring is essential when using 1,3-Dipropylxanthine in clinical settings.

CAS No. 31542-62-8, the unique identifier for 1,3-Dipropylxanthine, is crucial for researchers and clinicians to accurately reference this compound in scientific literature and regulatory documents. The use of standardized chemical identifiers ensures consistency and precision in communication across different scientific disciplines.

In recent years, advancements in computational chemistry and molecular modeling have provided deeper insights into the binding interactions between 1,3-Dipropylxanthine and its target receptors. These studies have helped optimize the design of new derivatives with improved selectivity and potency. For instance, modifications to the propyl groups or the xanthine core have led to compounds with enhanced therapeutic profiles and reduced side effects.

The safety profile of 1,3-Dipropylxanthine has been evaluated through extensive preclinical studies. Animal models have shown that this compound is generally well-tolerated at therapeutic doses, with minimal adverse effects on cardiovascular function or other organ systems. However, as with any new drug candidate, thorough clinical trials are necessary to fully assess its safety and efficacy in human subjects.

CAS No. 31542-62-8-based research continues to expand our understanding of adenosine receptor biology and its implications for human health. Ongoing studies are exploring the potential of 1,3-Dipropylxanthine-like compounds in treating a wide range of conditions beyond neurological disorders and respiratory diseases. For example, preliminary evidence suggests that these compounds may have anti-inflammatory properties that could be beneficial in managing autoimmune disorders such as rheumatoid arthritis.

In conclusion, 1,3-Dipropylxanthine (CAS No. 31542-62-8) represents a promising avenue for drug development due to its unique pharmacological properties and potential therapeutic applications. As research progresses, it is likely that this compound will continue to play a significant role in advancing our knowledge of adenosine receptor function and developing novel treatments for various medical conditions.

• 28822-58-4(3-Isobutyl-1-methylxanthine)
• 2850-36-4(1,3-Dibutylxanthine)
• 69-89-6(Xanthine)
• 5967-84-0(Theophylline monohydrate)
• 317-34-0(Aminophylline)
• 1076-22-8(3-Methylxanthine)
• 109987-37-3(1H-Purine-2,6-dione-2-13C,3,7-dihydro-1-(methyl-d3)- (9CI))
• 332062-08-5(Fmoc-S-3-amino-4,4-diphenyl-butyric acid)
• 1270529-38-8(1,2,3,4,5,6-Hexahydro-[2,3]bipyridinyl-6-ol)
• 2680771-01-9(4-cyclopentyl-3-{(prop-2-en-1-yloxy)carbonylamino}butanoic acid)